Quest Laboratories Ltd, originally established as a private entity in 1998, transitioned to a public limited company in January 2024. The company specializes in the manufacturing of a wide range of pharmaceutical formulations, including antibiotics, antimalarials, and diabetes treatments, marketed under the 'Quest Laboratories Limited' trademark. It offers ethical, generic, and over-the-counter drugs in various forms such as tablets and ointments.
Quest Laboratories holds WHO Schedule M GMP and GLP certifications, ensuring adherence to high-quality standards in pharmaceutical production. With the capability to manufacture over 600 formulations, the company routinely produces 250 to 300 based on market demand, supported by a versatile manufacturing facility. This infrastructure enables rapid adaptation to changes in product mixes. The company is ISO 9001:2015 certified, emphasizing its commitment to quality management. Quest Laboratories is preparing for an Initial Public Offering, aiming to issue 44,50,000 equity shares.
